No scientist has done more to bring the idea that aging can be treated -- and perhaps reversed -- into mainstream public consciousness than David Sinclair. A professor of genetics at Harvard Medical School, Sinclair has spent over two decades investigating the molecular mechanisms of aging, building biotech companies, publishing a bestselling book, and making headline-grabbing claims about age reversal in laboratory mice. He is simultaneously one of the most influential and most debated figures in longevity science -- a scientist whose ambition, visibility, and willingness to push boundaries have earned him both devoted followers and fierce critics.
Australian Origins
David Andrew Sinclair was born in 1969 in Sydney, Australia. His parents were Hungarian immigrants who had fled communist rule, and Sinclair has spoken about how their experiences shaped his drive and resilience. He studied biochemistry at the University of New South Wales, where he became interested in the molecular biology of aging. His PhD research focused on the genetics of yeast aging, specifically how repetitive ribosomal DNA sequences accumulate as extrachromosomal circles in aging yeast cells, contributing to cellular senescence.
In 1995, Sinclair moved to MIT for a postdoctoral fellowship in the laboratory of Leonard Guarente, one of the founding figures of modern aging genetics. It was in Guarente's lab that Sinclair first encountered sirtuins -- a family of proteins that would become the central focus of his career.
Sirtuins and NAD+
Sirtuins are a family of enzymes (SIRT1 through SIRT7 in mammals) that regulate critical cellular processes including DNA repair, gene expression, metabolism, and inflammation. They require the coenzyme nicotinamide adenine dinucleotide (NAD+) to function, and NAD+ levels decline significantly with age. Sinclair's central hypothesis has been that this age-related decline in NAD+ impairs sirtuin function, contributing to the molecular deterioration that characterizes aging.
In Guarente's lab, Sinclair helped demonstrate that the yeast sirtuin SIR2 plays a direct role in extending yeast lifespan. When he established his own laboratory at Harvard Medical School in 1999, he set out to determine whether boosting sirtuin activity in mammals could slow or reverse aging.
The Resveratrol Story
In 2003, Sinclair's lab published a paper in Nature reporting that resveratrol -- a compound found in red wine, grapes, and certain berries -- could activate SIRT1 and extend the lifespan of yeast. Follow-up studies suggested that resveratrol could also improve the health and lifespan of mice fed a high-fat diet, mimicking some of the benefits of caloric restriction.
The resveratrol findings generated enormous public excitement and media coverage. Red wine sales reportedly increased. Sinclair co-founded Sirtris Pharmaceuticals to develop sirtuin-activating compounds (STACs), and in 2008, GlaxoSmithKline (GSK) acquired Sirtris for $720 million -- one of the largest acquisitions of a pre-revenue biotech company in history at that time.
However, the resveratrol story also generated significant scientific controversy. Other laboratories struggled to replicate some of the findings. Questions arose about whether resveratrol truly activated SIRT1 directly or acted through other mechanisms. GSK eventually discontinued its sirtuin-activating drug programs, and the resveratrol hypothesis fell out of favor in some quarters of the scientific community. Sinclair has maintained that the core biology remains valid while acknowledging that the initial excitement outpaced the evidence.
The Information Theory of Aging
Sinclair's most ambitious theoretical contribution is what he calls the Information Theory of Aging. The core idea is that aging is not primarily caused by genetic mutations but by the loss of epigenetic information -- the chemical modifications and structural changes to DNA and histones that determine which genes are turned on or off in each cell.
According to Sinclair, the epigenome functions like the software running on the hardware of DNA. Over time, as cells respond to damage, stress, and normal wear, their epigenetic settings become scrambled. Cells lose their identity -- a liver cell begins to express genes that should only be active in other tissues, for example. This loss of cellular identity, Sinclair argues, is the fundamental driver of aging.
The Information Theory predicts that if epigenetic information could be restored, aging could be reversed. The cell's hardware (DNA) is largely intact in old age; it is the software (epigenome) that has degraded. This idea connects directly to the work of Shinya Yamanaka, whose four reprogramming factors can reset a cell's epigenome to an embryonic state.
Age Reversal in Mice: The OSK Experiment
In 2020, Sinclair's lab published a landmark paper in Nature demonstrating that a modified version of Yamanaka's reprogramming protocol could reverse aging in the eyes of elderly mice. Using three of the four Yamanaka factors -- OCT4, SOX2, and KLF4 (the "OSK" factors), deliberately omitting c-MYC due to its cancer-promoting potential -- the team showed that damaged retinal ganglion cells in aged mice could be rejuvenated. The treated mice regained youthful gene expression patterns and recovered lost vision.
The paper was a sensation. It provided the most compelling evidence to date that epigenetic reprogramming could reverse aging in living tissue without causing tumors. Sinclair described it as proof of concept for the Information Theory of Aging: if restoring the epigenome could reverse aging in one tissue, it might work in others.
In 2023, however, the story took a more complicated turn when Sinclair's lab retracted a subsequent paper in Cell that had claimed to demonstrate age reversal across multiple tissues in mice using a chemical cocktail approach. The retraction, attributed to concerns about data integrity, drew scrutiny and fueled ongoing debates about reproducibility in the Sinclair lab.
"Lifespan" and Public Advocacy
In 2019, Sinclair published "Lifespan: Why We Age -- and Why We Don't Have To," a bestselling book that brought his ideas to a general audience. The book argues that aging should be classified as a disease and treated with the same urgency as cancer or heart disease. Sinclair lays out his personal longevity regimen, which includes NMN (nicotinamide mononucleotide, an NAD+ precursor), resveratrol, metformin, and intermittent fasting.
The book made Sinclair a celebrity in the wellness and longevity communities. His social media presence, podcast appearances, and public lectures have given him a platform that few academic scientists enjoy. But they have also drawn criticism from peers who worry that Sinclair's public claims sometimes outpace the peer-reviewed evidence, particularly regarding NAD+ supplements and specific longevity interventions.
Tally Health and Commercial Ventures
Sinclair has co-founded or been involved in more than a dozen biotech companies. Among the most recent is Tally Health, a consumer-facing company that offers biological age testing based on epigenetic clocks and provides personalized recommendations for slowing biological aging. The company represents Sinclair's vision of making longevity science accessible to ordinary consumers, though it has also raised questions about the commercialization of aging research.
Controversies and Debates
Sinclair's career has been marked by recurring controversies. The resveratrol replication failures, the Cell retraction, and disagreements about the clinical significance of NAD+ supplementation have all generated criticism. Some prominent gerontologists have accused Sinclair of hype, arguing that his public statements create unrealistic expectations about near-term age reversal.
Sinclair's defenders counter that he has consistently pushed the field forward, generating testable hypotheses and attracting unprecedented funding and public interest to aging research. The debate over Sinclair's legacy is, in many ways, a proxy for a deeper tension in science: between the cautious norms of academic publishing and the urgency of communicating transformative possibilities to the public.
Recent Developments (2025–2026)
Sinclair's most significant milestone came in early 2026: Life Biosciences, the biotech company he co-founded, received FDA approval for a Phase 1 clinical trial of partial epigenetic reprogramming to restore vision in patients with glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION). This represents the first FDA-approved human trial specifically testing age reversal through epigenetic reprogramming.
The company's drug candidate, ER-100, has shown the ability to restore DNA methylation patterns and improve neuronal regeneration in a primate eye disease model. At the World Government Summit 2026, Sinclair declared that "ageing could soon be reversible," pointing to the upcoming human trial results expected by late 2026 or early 2027.
Research Lab & Companies
- Sinclair Lab — Harvard Medical School, Paul F. Glenn Center
- Life Biosciences — Co-founder (epigenetic reprogramming, FDA Phase 1 approved)
- Tally Health — Co-founder (consumer biological age testing)
- InsideTracker — Co-founder (biomarker-based health optimization)
- Animal Biosciences — Co-founder (pet longevity)
- MetroBiotech — Co-founder (NAD+ therapeutics)
Legacy and Influence
Whatever the outcome of ongoing scientific debates, David Sinclair has permanently altered the landscape of longevity science. He popularized the idea that aging is a treatable condition, attracted billions of dollars in investment to the field, and provided a theoretical framework -- the Information Theory of Aging -- that has stimulated research worldwide. His work on epigenetic reprogramming, building on Yamanaka's discoveries, has opened one of the most promising avenues in all of biomedicine.
Whether Sinclair's boldest claims will be vindicated remains to be seen. But his influence on how the world thinks about aging -- not as an inevitability but as a problem to be solved -- is already secure.
